Overview
Bicycle Therapeutics reports Q3 net loss of $59.1 mln, increased R&D expenses
Company expects dose selection update for pivotal trial in Q1 2026
Strengthened leadership with new Board and Advisory Board appointments
Outlook
Bicycle Therapeutics expects financial runway into 2028
Company to provide Duravelo-2 trial update in 1Q 2026
Initial EphA2 human imaging data expected in 1H 2026
Result Drivers
INCREASED R&D EXPENSES - Higher R&D costs driven by zelenectide pevedotin development and other clinical programs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | -$59.10 mln | ||
Q3 Basic EPS | -$0.85 | ||
Q3 Operating Expenses | $77.28 mln | ||
Q3 Operating Incom | -$65.55 mln | ||
Q3 Pretax Profit | -$58.89 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $25.50, about 67.9% above its October 29 closing price of $8.18
Press Release: ID:nBw8XBhDCa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)